因疑似肝门部胆管癌切除患者中的IgG4相关胆管炎:30年三级医疗经验
本研究回顾性分析1984至2015年间因疑似肝门部胆管癌行手术的患者,发现323例中50例(15%)为良性病变,其中42%(21/50)诊断为IgG4相关胆管炎(IAC)。随访的12例IAC患者中9例出现需免疫抑制治疗的复发,表明IAC在术后多年仍活动。
要点
- 因疑似肝门部胆管癌切除的患者中,15%(50/323)为良性病变。
- 良性病变患者中42%(21/50)诊断为IgG4相关胆管炎。
- 随访的12例IAC患者中9例出现需免疫抑制治疗的复发。
核心结论
- 三十年因疑似肝门部胆管癌行肝和胆管切除的病例中,15%为模拟肝门部胆管癌的良性胆道疾病,其中42%明确诊断为IgG4相关胆管炎。
- IgG4相关疾病在多数IAC患者术后多年仍保持活动。
- 新型IAC诊断检测可能减少误诊、不必要的手术及危及生命的并发症。
研究设计与样本
- 单中心三级医疗中心30年(1984年至2015年)经验。
- 识别所有因疑似肝门部胆管癌在本院接受手术的良性病变患者。
- 由病理学家重新评估良性肝脏和胆管标本,并按IgG4相关疾病国际共识病理标准评分。
- 对仍存活的良性病变患者进行随访,结合HISORt组C标准(对类固醇的反应)及血清IgG4水平升高和/或新型IgG4/IgG RNA比值进行IAC临床诊断。
- 评估术后任何时间需免疫抑制治疗的复发性症状性疾病。
主要发现
- 323例因疑似肝门部胆管癌行手术的患者中,50例(15%)为良性病变。
- 50例良性病变患者中,42%(21/50)建立IAC诊断,其中组织学诊断17例,临床诊断4例。
- 其余良性病变患者诊断为未分类硬化性炎症、囊腺瘤或硬化性血管瘤。
- 随访的12例IAC患者中,9例出现需免疫抑制治疗的复发性疾病发作。
关键数值与推荐
- IAC诊断采用HISORt组C标准(对类固醇的反应)结合血清IgG4水平升高和/或新型IgG4/IgG RNA比值。
- 组织学诊断依据IgG4相关疾病国际共识病理标准评分。
- 良性病变患者中IAC比例为42%(n=21/50)。
- 因疑似肝门部胆管癌手术的患者中良性病变比例为15%(50/323)。
- 随访的12例IAC患者中9例出现需免疫抑制治疗的复发。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Distinguishing perihilar cholangiocarcinoma (PHC) from benign forms of sclerosing cholangitis affecting the hilar bile ducts is challenging, since histological confirmation of PHC is difficult to obtain and accurate non-invasive diagnostic tests are not available. IgG4-associated cholangitis (IAC), an imitator of PHC, may present with clinical and radiographical signs of PHC. IAC can be accurately diagnosed with a novel qPCR test. The aim of this study was to investigate the incidence and long-term activity of IAC in patients resected for PHC in a single tertiary center over a period of 30 years. METHODS: All patients with benign disease who underwent surgery for presumed PHC in our institute between 1984 and 2015 were identified. Benign liver and bile duct specimens were re-evaluated by a pathologist and scored according to international consensus pathology criteria for IgG4-related disease (IgG4-RD). Patients with benign disease still alive were followed-up and a clinical diagnosis of IAC was made using a combination of the HISORt group C (response to steroids) criteria and elevated serum IgG4 levels and/or the novel IgG4/IgG RNA ratio. Also, recurrent symptomatic disease at any time after surgery requiring immunosuppression was assessed. RESULTS: Out of 323 patients who underwent surgery for presumed PHC, 50 patients (15%) had benign disease. In 42% (n = 21/50) of these patients a histological (n = 17) or clinical (n = 4) diagnosis of IAC was established. The remaining patients were diagnosed with unclassified sclerosing inflammation, cystadenoma, or sclerosing hemangioma. Nine out of 12 IAC patients who were followed-up showed episodes of recurrent disease requiring immunosuppressive treatment. CONCLUSIONS: Liver and bile duct resections for PHC during three decades disclosed in 15% benign biliary disorders mimicking PHC of which 42% were definitely diagnosed as IAC. IgG4-RD remains active in the majority of patients with IAC years after surgery. Novel diagnostic tests for IAC might reduce misdiagnosis, unnecessary surgery, and life-threatening complications.
引用
- Roos E, Hubers LM, Coelen RJS, et al. IgG4-Associated Cholangitis in Patients Resected for Presumed Perihilar Cholangiocarcinoma: a 30-Year Tertiary Care Experience. Am J Gastroenterol. 2018. PMID: 29549357. doi:10.1038/s41395-018-0036-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。